Gamma-secretase-mediated Notch3 signaling is involved in smooth muscle cell (SMC) hyper-activity and proliferation leading to
pulmonary arterial hypertension (PAH). In addition,
Propylthiouracil (PTU), beyond its anti-thyroid action, has suppressive effects on
atherosclerosis and PAH. Here, we investigated the possible involvement of
gamma-secretase-mediated Notch3 signaling in PTU-inhibited PAH. In rats with
monocrotaline-induced PAH, PTU
therapy improved pulmonary arterial
hypertrophy and hemodynamics. In vitro, treatment of PASMCs from
monocrotaline-treated rats with PTU inhibited their proliferation and migration. Immunocyto, histochemistry, and western blot showed that PTU treatment attenuated the activation of Notch3 signaling in PASMCs from
monocrotaline-treated rats, which was mediated via inhibition of
gamma-secretase expression especially its
presenilin enhancer 2 (Pen-2) subunit. Furthermore, over-expression of Pen-2 in PASMCs from control rats increased the capacity of migration, whereas knockdown of Pen-2 with its respective
siRNA in PASMCs from
monocrotaline-treated rats had an opposite effect. Transfection of PASMCs from
monocrotaline-treated rats with Pen-2
siRNA blocked the inhibitory effect of PTU on PASMC proliferation and migration, reflecting the crucial role of Pen-2 in PTU effect. We present a novel cell-signaling paradigm in which overexpression of Pen-2 is essential for experimental
pulmonary arterial hypertension to promote motility and growth of smooth muscle cells.
Propylthiouracil attenuates experimental PAH via suppression of the
gamma-secretase-mediated Notch3 signaling especially its
presenilin enhancer 2 (Pen-2) subunit. These findings provide a deep insight into the pathogenesis of PAH and a novel therapeutic strategy.